Verratti Mark 4

What Happened
Mark Verratti, Chief Operating Officer of Myriad Genetics, was awarded 32,810 performance-based restricted stock units (PSUs) on February 2, 2026. The Form 4 reports the acquisition as 32,810 shares at $0.00 (grant), listed as an award rather than an open-market purchase or sale. The PSUs are contingent on achieving pre-determined performance metrics and vest on March 15, 2026 if those metrics are met.

Key Details

• Transaction date: 2026-02-02; reported on Form 4 filed 2026-02-03 (timely within the two-business-day filing window).
• Transaction: Grant/award (code A) of 32,810 shares at $0.00 — reported acquisition value $0.
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: These are performance-based RSUs initially granted March 15, 2023; the Compensation & Human Capital Committee determined the final award amount on Feb 2, 2026 based on achieved performance metrics. Each PSU is a contingent right to receive one share and vests March 15, 2026.

Context
PSUs are a form of compensation tied to company performance; receiving an award is routine for executives and does not represent an open-market buy or sell. The grant reflects completion of the performance-period evaluation (final award determination), but actual shares will only be issued if the performance and vesting conditions are satisfied.